CO5261555A1 - Linezolid-forma cristalina ii - Google Patents

Linezolid-forma cristalina ii

Info

Publication number
CO5261555A1
CO5261555A1 CO01005901A CO01005901A CO5261555A1 CO 5261555 A1 CO5261555 A1 CO 5261555A1 CO 01005901 A CO01005901 A CO 01005901A CO 01005901 A CO01005901 A CO 01005901A CO 5261555 A1 CO5261555 A1 CO 5261555A1
Authority
CO
Colombia
Prior art keywords
linezolid
crystal form
oxazolidinyl
mfi
jpeg
Prior art date
Application number
CO01005901A
Other languages
English (en)
Inventor
Michael David Bergren
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22658183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5261555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CO5261555A1 publication Critical patent/CO5261555A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

(S)-N-[[3-[3-fluoro-4-(4-morfolinil)fenil]-2-oxo-5-oxazolidinil]metil]acetamida en cristales de "Forma II" con un espectro de difracción del polvo con rayos X de: Espaciamiento d (Á) Ángulo dos-teta (°) Intensidad relativa (%)12.44 7.10 2 9.26 9.54 9 6.37 13.88 6 6.22 14.23 24 5.48 16.18 3 5.28 16.79 100 5.01 17.69 2 4.57 19.41 4 4.50 19.69 2 4.45 19.93 6 4.11 21.61 15 3.97 22.39 23 3.89 22.84 4 3.78 23.52 7 3.68 24.16 1 3.52 25.28 13 3.34 26.66 1 3.30 27.01 3 3.21 27.77 1<EMI FILE="01005901_1" ID="1" IMF=JPEG >
CO01005901A 2000-02-02 2001-01-26 Linezolid-forma cristalina ii CO5261555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17983700P 2000-02-02 2000-02-02

Publications (1)

Publication Number Publication Date
CO5261555A1 true CO5261555A1 (es) 2003-03-31

Family

ID=22658183

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01005901A CO5261555A1 (es) 2000-02-02 2001-01-26 Linezolid-forma cristalina ii

Country Status (31)

Country Link
EP (1) EP1255754B1 (es)
JP (1) JP5235256B2 (es)
KR (3) KR100864745B1 (es)
CN (1) CN1221547C (es)
AR (1) AR027261A1 (es)
AT (1) ATE297920T1 (es)
AU (1) AU782138B2 (es)
BR (1) BR0107667A (es)
CA (1) CA2395603C (es)
CO (1) CO5261555A1 (es)
CZ (1) CZ302292B6 (es)
DE (1) DE60111497T2 (es)
DK (1) DK1255754T3 (es)
EA (1) EA004434B1 (es)
EE (1) EE05197B1 (es)
ES (1) ES2242728T3 (es)
HK (1) HK1051196A1 (es)
HU (1) HUP0301076A3 (es)
IL (1) IL151010A0 (es)
MX (1) MXPA02007471A (es)
MY (1) MY122829A (es)
NO (2) NO323459B1 (es)
NZ (1) NZ520541A (es)
PE (1) PE20011086A1 (es)
PL (1) PL356433A1 (es)
PT (1) PT1255754E (es)
SI (1) SI1255754T1 (es)
SK (1) SK287025B6 (es)
TW (1) TWI297687B (es)
WO (1) WO2001057035A1 (es)
ZA (1) ZA200205162B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490643B1 (ko) * 2002-10-29 2005-05-19 한국과학기술연구원 새로운 메틸리덴 피페리딘일 옥사졸리딘온 유도체 및이들의 제조방법
ES2331001T3 (es) 2003-10-16 2009-12-18 Symed Labs Limited Forma cristalina de linezolid.
EP1737850B1 (en) 2004-04-19 2007-10-03 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
MX2007000084A (es) * 2004-06-29 2007-06-14 Teva Pharma Formas solidas de linezolid y procesos para la preparacion delas mismas.
JP2007504173A (ja) * 2004-06-29 2007-03-01 テバ ファーマシューティカル インダストリーズ リミティド リネゾリドのｉｖ型結晶
JP2008530028A (ja) 2005-02-24 2008-08-07 テバ ファーマシューティカル インダストリーズ リミティド リネゾリッド中間体の調製方法
WO2007002314A2 (en) * 2005-06-22 2007-01-04 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod maleate
DE602006001699D1 (de) * 2005-07-20 2008-08-21 Teva Pharma Stabile pharmazeutische Zusammensetzung mit Linezolid Form IV
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
CA2703011A1 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2011050826A1 (en) 2009-10-28 2011-05-05 Synthon B.V. Process for making crystalline form a of linezolid
AU2011245302A1 (en) 2010-04-30 2012-11-22 Indiana University Research And Technology Corporation Processes for preparing linezolid
EP2603506A1 (en) 2010-08-11 2013-06-19 Synthon BV Process for making linezolid
EP2603505A1 (en) 2010-08-11 2013-06-19 Synthon BV Process for making linezolid
WO2012114354A1 (en) * 2011-02-24 2012-08-30 Lee Pharma Limited Anhydrous linezolid crystalline form-ii
WO2012119653A1 (en) 2011-03-09 2012-09-13 Synthon Bv Process for making crystalline form a of linezolid
CN102731341A (zh) * 2011-04-13 2012-10-17 上海医药工业研究院 用于制备利奈唑胺的中间体及其制备方法
CN102766106A (zh) * 2011-05-03 2012-11-07 江苏豪森医药集团有限公司 利奈唑胺的新晶型及其制备方法
CN102399200B (zh) * 2011-12-14 2013-12-04 浙江新东港药业股份有限公司 一种利用悬浮结晶法制备利奈唑胺晶型ⅰ的方法
EP2852580A1 (en) 2012-01-24 2015-04-01 Jubilant Life Sciences Ltd. Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
CN102643245A (zh) * 2012-04-10 2012-08-22 杭州华东医药集团生物工程研究所有限公司 一种利奈唑胺晶型及其制备方法
EP2917189B1 (en) 2012-11-09 2016-08-17 Synthon BV Process for making linezolid
WO2019097242A1 (en) * 2017-11-16 2019-05-23 Persica Pharmaceuticals Ltd. Linezolid formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
KR100530297B1 (ko) * 1996-04-11 2005-11-22 파마시아 앤드 업존 캄파니 엘엘씨 옥사졸리디논의 제조 방법
EP1028940B1 (en) * 1997-11-07 2007-04-18 Pharmacia & Upjohn Company LLC Process to produce oxazolidinones

Also Published As

Publication number Publication date
KR20070087178A (ko) 2007-08-27
EE200200420A (et) 2003-12-15
AR027261A1 (es) 2003-03-19
KR20020072300A (ko) 2002-09-14
ES2242728T3 (es) 2005-11-16
JP2003522175A (ja) 2003-07-22
DE60111497T2 (de) 2006-05-18
AU3275501A (en) 2001-08-14
WO2001057035A1 (en) 2001-08-09
JP5235256B2 (ja) 2013-07-10
AU782138B2 (en) 2005-07-07
CN1394207A (zh) 2003-01-29
NO323459B1 (no) 2007-05-14
BR0107667A (pt) 2002-10-08
CA2395603C (en) 2010-03-23
PE20011086A1 (es) 2001-10-04
EP1255754A1 (en) 2002-11-13
EP1255754B1 (en) 2005-06-15
HK1051196A1 (en) 2003-07-25
CA2395603A1 (en) 2001-08-09
NO20023654L (no) 2002-08-01
NZ520541A (en) 2004-02-27
KR100864745B1 (ko) 2008-10-22
NO20023654D0 (no) 2002-08-01
MXPA02007471A (es) 2002-12-13
PT1255754E (pt) 2005-11-30
CN1221547C (zh) 2005-10-05
NO20065836L (no) 2002-08-01
MY122829A (en) 2006-05-31
KR100781815B1 (ko) 2007-12-03
TWI297687B (en) 2008-06-11
EE05197B1 (et) 2009-08-17
ZA200205162B (en) 2003-09-29
CZ302292B6 (cs) 2011-02-09
DE60111497D1 (de) 2005-07-21
CZ20022635A3 (cs) 2002-10-16
ATE297920T1 (de) 2005-07-15
PL356433A1 (en) 2004-06-28
HUP0301076A2 (hu) 2003-08-28
IL151010A0 (en) 2003-02-12
DK1255754T3 (da) 2005-08-22
SK9942002A3 (en) 2002-11-06
EA004434B1 (ru) 2004-04-29
SK287025B6 (sk) 2009-10-07
SI1255754T1 (sl) 2005-12-31
EA200200819A1 (ru) 2003-02-27
HUP0301076A3 (en) 2004-06-28
KR20080044358A (ko) 2008-05-20

Similar Documents

Publication Publication Date Title
CO5261555A1 (es) Linezolid-forma cristalina ii
HK1090294A1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4- oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate ;
SI1526132T1 (sl) Substituirani derivati oksazolidinona in njihova uporaba kot inhibitorji faktorja Xa
DK1185299T3 (da) Anvendelse af antistoffer mod CD20 til behandling af graft versus host disease
CY1105055T1 (el) Θepαπεια γαστρεντepικων στρωματικων ογκων
DE60126167D1 (de) Spritzenzylinder und Halter
GB0315111D0 (en) Substituted 5-membered ring compounds and their use
JP2003522175A5 (es)
GEP20084341B (en) Aminoheteroaryl compounds as protein kinase inhibitors
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
CO5300398A1 (es) Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek
HK1077534A1 (en) Use of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2- yl]phenyl)pyridine-3-sulphonamide in the treatment of cancer
HUP0301248A3 (en) Thiadiazole and oxadiazole derivatives, their use as phosphodiesterase-7 inhibitors
MEP33308A (en) Benzimidazole derivative and use as angiotensin ii antagonist
NO992226L (no) Nye forbindelser for anvendelse som neuro-protektive midler
NZ332990A (en) oral pharmaceutical composition containing a H+, K+-atpase inhibitor having a extended blood plasma profile
DE60112903D1 (de) Oxazolidinon-thioamide mit piperazinamid-substituenten
DE60042221D1 (de) Lichtempfindliche keramische Zusammensetzungen, die Polycarbonatpolymere enthalten
EG23929A (en) Isoxazolines derivatives and their use as antidepressants
UA92592C2 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent such as taxane for the treatment of cancer
DE69811717T2 (de) Verwendung von oxazolidinonderivate zur behandlung von arthritis
EA200300835A1 (ru) Новые производные алкилфенилиминоимидазолидина для лечения недержания мочи
ATE323066T1 (de) Phenyl-und phenylalkyl-substituierte ethanolamine und ethylendiamine
BR0111226A (pt) Composição oral compreendendo greda branca
ITAP20020012U1 (it) Modulo per selezionare grazie alla forza di gravita&#39;, raggruppare in p ile, conteggiare e distribuire monete di varie misure

Legal Events

Date Code Title Description
FC Application refused